Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i> -Amplified Breast CancersMeghan M. Joly, Rebecca S. Cook, Brent N. Rexer et al.|Cancer Research|2016Cited by 83
Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasisMeghan M. Joly, Rebecca S. Cook, Bayley A. Jones et al.|Breast Cancer Research|2017Cited by 79
Data from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast CancersMeghan M. Joly, Rebecca S. Cook, Donna J. Hicks et al.|Unknown|2023Cited by 0
Supplemental Figure legends and Tables from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast CancersMeghan M. Joly, Rebecca S. Cook, Donna J. Hicks et al.|Unknown|2023Cited by 0
Supplemental Figures from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast CancersMeghan M. Joly, Rebecca S. Cook, Donna J. Hicks et al.|Unknown|2023Cited by 0